跳至主要内容
临床试验/NCT01106742
NCT01106742已完成2 期

Potential Anti-inflammatory Effect of Mushroom Extract From Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)

Ullevaal University Hospital2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2009年3月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
20
试验地点
2
主要终点
The ultimate goal is to see whether the ABM can be used as additional treatment of IBD.

研究概览

简要总结

Based on the anti-inflammatory and stabilising effect of the AbM, (Agaricus Blazei Murill) based mushroom extract AndoSanTM on cytokine release in blood in vivo and ex vivo in healthy volunteers after 12 days consumption, the aim in this study is to investigate whether same effect is valid in patients with IBD (inflammatory bowel disease). In addition, calprotectin an abundant cytosolic protein in neutrophils and a surrogate marker for degree of intestinal inflammation will be measured in blood and feces of these patients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Moderate disease activity

排除标准

  • No use of Imurel (Azathioprin) or anti-TNF treatment

结局指标

主要结局

The ultimate goal is to see whether the ABM can be used as additional treatment of IBD.

时间窗: 12 days

次要结局

未报告次要终点

研究者

发起方
Ullevaal University Hospital
申办方类型
Other

研究点 (2)

Loading locations...

相似试验